Invented by Ula V. Jurkunas, Schepens Eye Research Institute Inc
The market for compositions of and methods for the treatment of corneal endothelium disorders is rapidly growing as more people are experiencing these conditions. The corneal endothelium is a delicate layer of cells that line the inner surface of the cornea, responsible for maintaining the cornea’s clarity and regulating fluid balance. When these cells become damaged or dysfunctional, it can lead to various corneal endothelium disorders, such as Fuchs’ endothelial dystrophy, corneal edema, and bullous keratopathy.
Traditionally, the treatment options for corneal endothelium disorders have been limited. In severe cases, a corneal transplant may be necessary, where the damaged endothelium is replaced with healthy donor tissue. However, this procedure is invasive, requires a long recovery period, and is dependent on the availability of donor tissue.
In recent years, there has been significant progress in developing alternative treatments for corneal endothelium disorders. One promising approach is the use of compositions that can stimulate the regeneration of corneal endothelial cells. These compositions often contain growth factors, cytokines, and other bioactive molecules that promote cell proliferation and migration. By applying these compositions to the cornea, researchers hope to stimulate the growth of new endothelial cells and restore their normal function.
Another area of research focuses on developing methods for delivering these compositions to the cornea. One approach is the use of specialized contact lenses or eye drops that can release the therapeutic compounds over an extended period. These delivery methods offer a non-invasive and patient-friendly alternative to traditional treatments.
The market for compositions and methods for the treatment of corneal endothelium disorders is driven by several factors. Firstly, the increasing prevalence of corneal endothelium disorders, particularly among the aging population, has created a significant demand for effective treatments. Additionally, the limitations of current treatment options, such as corneal transplantation, have spurred the development of innovative solutions.
Several companies and research institutions are actively involved in developing and commercializing these compositions and methods. They are conducting clinical trials to assess the safety and efficacy of their products and are working towards obtaining regulatory approvals. The market is expected to witness substantial growth in the coming years as these treatments become more widely available.
However, there are still challenges to overcome in this field. One major hurdle is ensuring the long-term stability and functionality of regenerated corneal endothelial cells. Researchers need to develop strategies to prevent the recurrence of endothelial cell damage and maintain the health of the cornea over time.
In conclusion, the market for compositions of and methods for the treatment of corneal endothelium disorders is expanding rapidly. The development of innovative therapies that can stimulate the regeneration of corneal endothelial cells offers new hope for patients suffering from these conditions. With ongoing research and advancements in technology, the future looks promising for those seeking effective and non-invasive treatments for corneal endothelium disorders.
The Schepens Eye Research Institute Inc invention works as follows
This application discloses pharmaceutical formulations (e.g. oral, parenteral, or topical ophthalmic formulations), for the treatment of Fuchs endothelial dystrophy (FECD), with one or two Nrf2 activators, and/or antioxidants that target mitochondria. These compositions can be applied topically to the eye, and they are effective for treating FECD. The invention also provides methods for treating FECD in a patient in need of treatment by topical administration of one or more Nrf2 activaters and/or mitochondrially.
Background for Compositions of and methods for treatment of corneal Endothelium Disorders
Mitochondrial Targeted Antioxidants
Nrf2-Antioxidant Response Element (ARE)-Driven Antioxidants
Methods for Use
Fuchs Endothelial Corneal Dystrophy
Pseudophakic Bullous Keratopathy” (PBK) and “Aphakic Bullous Keratopathy” (ABK).
Endothelial cell loss
Example 2: Evidence of Oxidative stress in the Pathogenesis Fuchs Endothelial Corneal Dystrophy
Oxidant/Antioxidant Imbalance of FECD CE
Increased oxidative DNA damage in FECD CE”.
Colocalization Of Oxidative Damage To DNA And Mitochondria”.
to view the patent on Google Patents.